This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Bayer Healthcare LLC. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Innovator Spotlight: Xiao-Gao Liu, Pioneering Rho Kinase Inhibitor Technologies
Introduction:
Xiao-Gao Liu, a talented inventor based in New Haven, CT, is making significant strides in the field of pharmaceuticals with his innovative work on Rho kinase inhibitors. Holding two patents and working at Bayer Healthcare LLC, Liu is at the forefront of cutting-edge research that is poised to revolutionize the treatment of various medical conditions.
Latest Patents:
Liu's latest patents showcase his expertise in the development of Rho kinase inhibitors. His invention of substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors demonstrates the compounds' efficacy in inhibiting tumor growth, treating erectile dysfunction, and addressing coronary heart disease. Furthermore, his process for preparing quinazoline Rho kinase inhibitors underscores the potential use of these compounds in treating hypertension and other related conditions.
Career Highlights:
Xiao-Gao Liu's career highlights reflect his commitment to advancing pharmaceutical innovation. With a focus on Rho kinase inhibitors, he has positioned himself as a key figure in the development of novel therapeutic solutions. His contributions have not only expanded the current understanding of Rho kinase inhibitors but also paved the way for new treatment modalities in critical areas such as oncology and cardiovascular health.
Collaborations:
In his professional journey, Liu has had the privilege of collaborating with esteemed colleagues such as Uday R Khire and Davoud Asgari. Together, they have synergized their expertise to drive forward groundbreaking research initiatives and expand the scope of pharmaceutical innovation. Through effective partnerships and shared knowledge, Liu and his coworkers have achieved remarkable milestones in the field of Rho kinase inhibitors.
Conclusion:
Xiao-Gao Liu's dedication to pioneering Rho kinase inhibitor technologies is truly commendable. With his two patents and affiliation with Bayer Healthcare LLC, he continues to push the boundaries of pharmaceutical innovation and set new standards for therapeutic development. As a visionary inventor, Liu's work serves as a testament to the power of ingenuity and collaboration in driving scientific progress and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile